A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study)
Sponsor: Healx AI
This PHASE2 trial investigates 15q Duplication Syndrome and CDKL5 Deficiency Disease and is currently completed. Healx AI leads this study, which shows 17 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
17 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE2
-
May 2021 — Jun 2022 [monthly]
Completed PHASE2
▶ Show 12 earlier versions
-
Jan 2021 — May 2021 [monthly]
Completed PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Jan 2019 [monthly]
Recruiting PHASE2
First recorded
Sep 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Healx AI
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .